Mitsubishi Tanabe confirms plasma products spin-out, logs lacklustre sales
This article was originally published in Scrip
Japan's Mitsubishi Tanabe Pharma (MTP) has confirmed that it will spin out and merge its blood plasma fractionation operations with those of the Japanese Red Cross Society later this year.
You may also be interested in...
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.